A polystyrene-film-based device for engineered cardiac tissues enables accurate analysis of drug responses on contractile properties
Open Access
- 30 May 2025
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 25 (15) , 3682-3693
Abstract
Engineered heart tissues (EHTs) using human induced pluripotent stem cells provide a valuable in vitro platform for assessing pharmacological and toxicological effects on cardiac functions. EHT devices offer a feasible approach to readily evaluate drug responses on contractile properties, including contractile force and relaxation, by measuring the moving distance of pillars attached to EHTs. However, the absorption of small molecule compounds by polydimethylsiloxane (PDMS), the material commonly used to construct EHT devices, hinders the accurate evaluation of the pharmacodynamic properties of drug candidates on contractility. Here, we developed a low-absorption EHT device using polystyrene (PS) to address this issue. Moreover, we generated an original Python-based analysis program to avoid analytical bias when tracking pillar positions and analyzing the contractile waveform drawn from EHT movements. This analytical platform enables the detection of increased contractile force during EHT maturation and the negative inotropic effects of diltiazem and blebbistatin on EHT contractile functions. Moreover, EHTs with PS-based devices suppressed the absorption of a cardiotoxic drug, doxorubicin, thus allowing the detection of cardiotoxic effects even at low concentrations compared to EHTs grown on PDMS-based devices. Together, our EHT system represents a useful in vitro platform for accurate evaluations of drug responses by the human heart.Keywords
Funding Information
- Kyoto University Foundation
- Fondation Leducq (18CVD05)
- Japan Agency for Medical Research and Development (JP20bm0104001, JP21bm0804022, JP24mk0121280, JP22mk0101241, JP23bm1323001, JP23bm1423011, JP24bm1123054)
- Japan Society for the Promotion of Science (20K16218, 24K19055)
- Takeda Pharmaceutical Company
- Program for Creating STart-ups from Advanced Research and Technology (JPMJSF2323)
This publication has 35 references indexed in Scilit:
- Aligned human induced pluripotent stem cell-derived cardiac tissue improves contractile properties through promoting unidirectional and synchronous cardiomyocyte contractionBiomaterials, 2022
- Human Cardiac Ventricular‐Like Organoid Chambers and Tissue Strips From Pluripotent Stem Cells as a Two‐Tiered Assay for Inotropic ResponsesClinical Pharmacology & Therapeutics, 2019
- A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease ModelingCell, 2019
- Bioengineering an electro-mechanically functional miniature ventricular heart chamber from human pluripotent stem cellsBiomaterials, 2018
- SEBS elastomers for fabrication of microfluidic devices with reduced drug absorption by injection molding and extrusionMicrofluidics and Nanofluidics, 2017
- Small molecule absorption by PDMS in the context of drug response bioassaysBiochemical and Biophysical Research Communications, 2017
- Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte FunctionCell Reports, 2015
- Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytesBiomaterials, 2013
- Drug‐screening platform based on the contractility of tissue‐engineered muscleMuscle & Nerve, 2008
- Blebbistatin: use as inhibitor of muscle contractionPflügers Archiv - European Journal of Physiology, 2007